CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $17.75M, above the global median of $16.24M
- FinancialsAltman Z-Score 1.24: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.77BCNY560.10M · vs all stocks (USD)
Revenue (TTM)
443.29MCNY65.92M · vs all stocks (USD)
Profit Margin
-66.62%Beta
0.5630xvs all stocks
52-Week Change
45.60%vs all stocks
Market Capitalization
3.77BCNY560.10M · vs all stocks (USD)
Enterprise Value
4.10BCNY610.15M · vs all stocks (USD)
Price to Sales (TTM)
8.50xPrice to Book (MRQ)
6.47xEnterprise to Revenue
9.26xEnterprise to EBITDA
-58.51xGross Margin
33.93%Profit Margin
-66.62%Operating Margin
-21.98%Return on Assets (TTM)
-4.72%Return on Equity (TTM)
-39.31%Revenue (TTM)
443.29MCNY65.92M · vs all stocks (USD)
Revenue per Share (TTM)
4.46CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-23.10%Gross Profit (TTM)
90.68MCNY13.49M · vs all stocks (USD)
EBITDA (TTM)
-70.13MCNY-10.43M · vs all stocks (USD)
Net Income (TTM)
-295.33MCNY-43.92M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-40.57%Operating Cash Flow (TTM)
32.38MCNY4.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
119.39MCNY17.75M · vs all stocks (USD)
5-Year Average Dividend Yield
0.61%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
44.06MCNYFY2025 · Dec 31, 2025Revenue
471.29MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
351.80MCNYFY2025 · Dec 31, 2025Gross Profit
119.48MCNYFY2025 · Dec 31, 2025Operating Income
-84.77MCNY-12.61M · vs all stocks (USD)
Pre-tax Income
-343.39MCNYFY2025 · Dec 31, 2025Income Tax Expense
-7.04MCNYFY2025 · Dec 31, 2025Net Income
-336.35MCNYFY2025 · Dec 31, 2025EBIT
-309.05MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.72MCNYFY2025 · Dec 31, 2025Research & Development
12.15MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
113.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.65MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
34.34MCNYFY2025 · Dec 31, 2025EPS (Basic)
-3.34CNYFY2025 · Dec 31, 2025EPS (Diluted)
-3.34CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
99.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
99.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-336.35MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-326.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-341.98MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
87.82MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-336.35MCNYFY2025 · Dec 31, 2025Other Non-cash Items
35.66MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.05MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.89MCNYFY2025 · Dec 31, 2025Capital Expenditures
-15.35MCNYFY2025 · Dec 31, 2025Net Acquisitions
5.38MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.75MCNYFY2025 · Dec 31, 2025Sale of Investments
924.97KCNYFY2025 · Dec 31, 2025Other Investing Activity
1.49MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-18.30MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
286.05MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-259.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-27.86MCNYFY2025 · Dec 31, 2025Other Financing Charges
31.04MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
29.24MCNYFY2025 · Dec 31, 2025Shares Outstanding
99.88MSharesUpdated Aug 21, 2026Float Shares
46.51MSharesUpdated Aug 21, 2026% Held by Insiders
49.25%vs all stocks
% Held by Institutions
1.43%vs all stocks
Total Cash (MRQ)
52.95MCNY7.87M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5300CNYUpdated Aug 21, 2026Total Debt (MRQ)
586.90MCNY87.28M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.01xCurrent Ratio (MRQ)
0.6280xBook Value per Share (MRQ)
5.46CNYUpdated Aug 21, 2026Total Assets
1.81BCNY269.82M · vs all stocks (USD)
Total Current Assets
589.90MCNYFY2025 · Dec 31, 2025Total Liabilities
1.25BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.22BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
314.93MCNYFY2025 · Dec 31, 2025Total Current Liabilities
930.51MCNYFY2025 · Dec 31, 2025Cash
100.78MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
107.71MCNYFY2025 · Dec 31, 2025Other Short-term Investments
252.20KCNYFY2025 · Dec 31, 2025Accounts Receivable
226.74MCNYFY2025 · Dec 31, 2025Inventory
163.14MCNYFY2025 · Dec 31, 2025Accounts Payable
449.69MCNYFY2025 · Dec 31, 2025Short-term Debt
388.77MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.37MCNYFY2025 · Dec 31, 2025Long-term Debt
246.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
99.88MCNYFY2025 · Dec 31, 2025Retained Earnings
-55.70MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
568.98MCNY84.61M · vs all stocks (USD)
52-Week Low
19.91CNYUpdated Aug 21, 202652-Week High
46.92CNYUpdated Aug 21, 202652-Week Change
45.60%vs all stocks
Beta
0.5630xvs all stocks
50-Day MA
37.63CNYUpdated Aug 21, 2026200-Day MA
29.80CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.81MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.00MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-2.96CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.24: grey zoneSignificant
Altman Z-Score: 1.24
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $17.75M, above the global median of $16.24MNotable
Levered free cash flow (USD): 17,754,218.032Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule